R. L. Priore - Concepedia

Author

R. L. Priore

Roswell Park Comprehensive Cancer Center

Also Known As

Priore, R. L., Priore, Roger, Priore, Roger L., R L Priore, R Priore, R. L. Priore, R. PRIORE, R. Priore, R.L. Priore, RL Priore

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Roswell Park Comprehensive Cancer Center University at Buffalo, State University of New York Buffalo General Medical Center University of Pittsburgh University of Rochester

About

R. L. Priore is an author at Roswell Park Comprehensive Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	987
2	Health Sciences	2	2	62
3	Natural Sciences	1	1	173
4	Public Health	1	1	231
5	Allergy	1	1	43

R. L. Priore

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis R. A. Rudick, Donald E. Goodkin, L. D. Jacobs, Neurology	1997	232
Diet in the Epidemiology of Carcinoma of the Prostate Gland<xref ref-type="fn" rid="fn2">2</xref><xref ref-type="fn" rid="fn3">3</xref><xref ref-type="fn" rid="fn4">4</xref> Saxon Graham, B Haughey, James R. Marshall, JNCI Journal of the National Cancer Institute NutritionPublic Health NutritionPathologyOncologyGenitourinary Cancer	1983	231
The binding of tranexamic acid to native (Glu) and modified (Lys) human plasminogen and its effect on conformation. Gabor Markus, R. L. Priore, F.C. Wissler Journal of Biological Chemistry BiochemistryNatural SciencesHuman PlasminogenBioanalysisGlycobiology	1979	173
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients L. Jacobs, DL Cookfair, RA Rudick, Multiple Sclerosis Journal	1995	115
Thromboembolism Prophylaxis in Chronic Atrial Fibrillation F Munschauer, R. L. Priore, Margaret M. Hens, Stroke	1997	111
Relative Reliability of Five Serially Measured Markers for Prognosis of Progression in Prostate Cancer<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref> C. S. Killian, Lawrence J. Emrich, M.C. Wang, JNCI Journal of the National Cancer Institute Prognostic EvaluationPrognostic BiomarkersUrologyGenitourinary CancerMedicine	1986	97
CELLULAR DIFFERENTIATION OF THE IMMUNE SYSTEM OF MICE G M Shearer, Gustavo Cudkowicz, Mary St. James Connell, The Journal of Experimental Medicine	1968	94
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. Harvey D. Preisler, Azra Raza, Amy Early, Journal of Clinical Oncology Hematological MalignancyOncologyMedian DurationMixed-phenotype Acute LeukemiaMalignant Blood Disorder	1987	90
Test-Retest Reliability of the Cognitive Lifetime Drinking History Marcia Russell, James R. Marshall, Maurizio Trevisan, American Journal of Epidemiology	1997	86
Comparison of flutamide and emcyt in hormone-refractory metastatic prostatic cancer☆ J.N. de Kernion, G.P. Murphy, R. L. Priore, Urology UrologyOncologyGenitourinary CancerMedicinePharmacotherapy	1988	59

Page 1